Non-Human Primates Capabilityx2a38631nandNon-Human Primates modelsof PharmaLegacy Laboratories (Shanghai) Co., Ltdis favored by the majority of customers love, We have established long-term cooperation with many partner, PDX Model,Osteoarthritis Modelfrom PharmaLegacymeet the needs of our customers. PharmaLegacystrength,abide by contract, keep faith, take quality and credit of contract,obtained the customer trust and praise.

PharmaLegacy Laboratories (Shanghai) Co., Ltd has been devoted to study the needs of PharmaLegacy industrial customers, ant tailored to customers demand and solutions. The advantage of PharmaLegacy lies not only in the industry-leading technology and the elite professional team, but also to provide excellent services in Pharmacodynamic evaluation test platform,humanized animal model,antibody research and development servi,and the enthusiasm of positive innovation and faith of respect promise . Become a customer trusted Efficient Non-Human Primates Capability integrated service providers, to help customers realize the business value of Non-Human Primates models, is PharmaLegacy unswerving mission and pursuit. Details: Non-human primates model (NHP) have closer phylogenetic relationship to human and the disease targets in NHP models share high cross-reactivity to the human target specific biological molecules which do not react with rodent counterpart. PharmaLegacy has therefore developed and validated serials of NHP platforms, covering Inflammation/ Autoimmune Diseases, Bone/Orthopedics, Respiratory Disease, as well as Pharmacokinetics Profiling Assay to test pharmacological effects and mechanisms of candidate drugs especially for therapeutic monoclonal antibodies. Experiments involving non-human primates (NHPs) include toxicity testing for medical and non-medical substances; studies of infectious disease, such as HIV and hepatitis; neurological studies; behavior and cognition; reproduction; genetics; and xenotransplantation. Around 65,000 NHPs are used every year in the United States, and around 7,000 across the European Union. Most of the NHPs used are one of three species of macaques, accounting for 79% of all primates used in research in the UK, and 63% of all federally funded research grants for projects using primates in the U.S. Lesser numbers of marmosets, tamarins, spider monkeys, owl monkeys, vervet monkeys, squirrel monkeys, and baboons are used in the UK and the US. Great Apes have not been used in the UK since a Government policy ban in 1998.
With the purpose of Quality first, service is paramount in PharmaLegacy, our strict product quality control system ensures that Humanized mice,Respiratory Disease Model and other products of high quality and stability. We have a first-class laboratory equipment and a highly experienced professional and technical team. In the future, we will continue to work hard and get win-win cooperation for a better tomorrow! For more information, please visit the official website: www.pharmalegacy.com
bio-equip.cn
PharmaLegacy Laboratories is a leading speciality pharmacology Contract Research Organization located in Shanghai Zhangjiang High-Tech Park, China. PharmaLegacy is equipped with a world-class facility, working to international pharmaceutical industrial standards. PharmaLegacy provides preclinical in vivo pharmacology efficacy services as well a therapeutic antibody discovery service program. Our state-of-the-art platforms include:· Pioneering work using CD34+ humanized mice that carry a human immune system, to test biologics for immuno-oncology therapeutic efficacy· An NHP platform for therapeutic biologics testing in a variety of immune diseases · An advanced antibody discovery platform based on single B cell antibody sequencing · An internationally recognized Bone/Orthopaedics platform to test both hard tissue disease therapeutic candidates and medical devicesPharmaLegacy offers a full range of preclinical pharmacology services for evaluating pharmacological effects of drug candidates in the areas of inflammation/auto-Immune diseases, lung injury, liver/metabolic diseases and oncology. Our NHP platform and CD34+ humanized mice models have helped dozens of clients with IND filings